#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-8	Apparent	_
1-2	9-16	Effects	_
1-3	17-19	of	_
1-4	20-26	Opioid	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
1-5	27-30	Use	_
1-6	31-33	on	_
1-7	34-40	Neural	_
1-8	41-50	Responses	_
1-9	51-53	to	_
1-10	54-60	Reward	_
1-11	61-63	in	_
1-12	64-71	Chronic	_
1-13	72-76	Pain	_
1-14	77-83	Neural	_
1-15	84-93	responses	_
1-16	94-96	to	_
1-17	97-107	incentives	_
1-18	108-111	are	_
1-19	112-119	altered	_
1-20	120-122	in	_
1-21	123-130	chronic	_
1-22	131-135	pain	_
1-23	136-139	and	_
1-24	140-142	by	_
1-25	143-149	opioid	_
1-26	150-153	use	_
1-27	154-155	.	_

2-1	156-158	To	_
2-2	159-169	understand	_
2-3	170-173	how	_
2-4	174-180	opioid	_
2-5	181-184	use	_
2-6	185-194	modulates	_
2-7	195-198	the	_
2-8	199-205	neural	_
2-9	206-214	response	_
2-10	215-217	to	_
2-11	218-230	reward/value	_
2-12	231-233	in	_
2-13	234-241	chronic	_
2-14	242-246	pain	_
2-15	247-248	,	_
2-16	249-251	we	_
2-17	252-260	compared	_
2-18	261-266	brain	_
2-19	267-277	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-20	278-286	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-21	287-296	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-22	297-304	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-23	305-306	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-24	307-311	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-25	312-313	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
2-26	314-323	responses	_
2-27	324-326	to	_
2-28	327-328	a	_
2-29	329-337	monetary	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
2-30	338-347	incentive	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
2-31	348-353	delay	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
2-32	354-355	(	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
2-33	356-359	MID	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
2-34	360-361	)	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
2-35	362-366	task	_
2-36	367-369	in	_
2-37	370-378	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-38	379-383	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-39	384-396	fibromyalgia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-40	397-403	taking	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-41	404-411	opioids	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-42	412-413	(	_
2-43	414-415	N	_
2-44	416-417	=	_
2-45	418-420	17	_
2-46	421-422	)	_
2-47	423-424	,	_
2-48	425-433	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-49	434-438	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-50	439-451	fibromyalgia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-51	452-455	not	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-52	456-462	taking	_
2-53	463-470	opioids	_
2-54	471-472	(	_
2-55	473-474	N	_
2-56	475-476	=	_
2-57	477-479	17	_
2-58	480-481	)	_
2-59	482-483	,	_
2-60	484-487	and	_
2-61	488-495	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
2-62	496-504	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
2-63	505-506	(	_
2-64	507-508	N	_
2-65	509-510	=	_
2-66	511-513	15	_
2-67	514-515	)	_
2-68	516-517	.	_

3-1	518-522	Both	_
3-2	523-529	groups	_
3-3	530-532	of	_
3-4	533-541	patients	_
3-5	542-546	with	_
3-6	547-559	fibromyalgia	_
3-7	560-566	taking	_
3-8	567-570	and	_
3-9	571-574	not	_
3-10	575-581	taking	_
3-11	582-589	opioids	_
3-12	590-593	had	_
3-13	594-601	similar	_
3-14	602-608	levels	_
3-15	609-611	of	_
3-16	612-616	pain	_
3-17	617-618	,	_
3-18	619-632	psychological	_
3-19	633-641	measures	_
3-20	642-643	,	_
3-21	644-647	and	_
3-22	648-656	clinical	_
3-23	657-665	symptoms	_
3-24	666-667	.	_

4-1	668-674	Neural	_
4-2	675-684	responses	_
4-3	685-687	in	_
4-4	688-691	the	_
4-5	692-699	nucleus	_
4-6	700-709	accumbens	_
4-7	710-712	to	_
4-8	713-724	anticipated	_
4-9	725-731	reward	_
4-10	732-735	and	_
4-11	736-744	non-loss	_
4-12	745-753	outcomes	_
4-13	754-757	did	_
4-14	758-761	not	_
4-15	762-768	differ	_
4-16	769-773	from	_
4-17	774-781	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-18	782-790	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-19	791-793	in	_
4-20	794-800	either	_
4-21	801-813	fibromyalgia	_
4-22	814-819	group	_
4-23	820-821	.	_

5-1	822-829	However	_
5-2	830-831	,	_
5-3	832-838	neural	_
5-4	839-848	responses	_
5-5	849-851	in	_
5-6	852-855	the	_
5-7	856-862	medial	_
5-8	863-873	prefrontal	_
5-9	874-880	cortex	_
5-10	881-889	differed	_
5-11	890-891	,	_
5-12	892-896	such	_
5-13	897-901	that	_
5-14	902-910	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-15	911-915	with	_
5-16	916-928	fibromyalgia	_
5-17	929-932	not	_
5-18	933-939	taking	_
5-19	940-947	opioids	_
5-20	948-960	demonstrated	_
5-21	961-974	significantly	_
5-22	975-982	altered	_
5-23	983-992	responses	_
5-24	993-995	to	_
5-25	996-1007	anticipated	_
5-26	1008-1015	rewards	_
5-27	1016-1019	and	_
5-28	1020-1028	non-loss	_
5-29	1029-1037	outcomes	_
5-30	1038-1046	compared	_
5-31	1047-1049	to	_
5-32	1050-1057	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-33	1058-1066	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-34	1067-1068	,	_
5-35	1069-1072	but	_
5-36	1073-1081	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-37	1082-1086	with	_
5-38	1087-1099	fibromyalgia	_
5-39	1100-1106	taking	_
5-40	1107-1114	opioids	_
5-41	1115-1118	did	_
5-42	1119-1122	not	_
5-43	1123-1124	.	_

6-1	1125-1132	Despite	_
6-2	1133-1144	limitations	_
6-3	1145-1154	including	_
6-4	1155-1158	the	_
6-5	1159-1162	use	_
6-6	1163-1165	of	_
6-7	1166-1176	additional	_
6-8	1177-1187	non-opioid	_
6-9	1188-1199	medications	_
6-10	1200-1202	by	_
6-11	1203-1215	fibromyalgia	_
6-12	1216-1224	patients	_
6-13	1225-1231	taking	_
6-14	1232-1239	opioids	_
6-15	1240-1241	,	_
6-16	1242-1247	these	_
6-17	1248-1259	preliminary	_
6-18	1260-1268	findings	_
6-19	1269-1276	suggest	_
6-20	1277-1287	relatively	_
6-21	1288-1289	“	_
6-22	1290-1300	normalized	_
6-23	1301-1302	”	_
6-24	1303-1309	neural	_
6-25	1310-1319	responses	_
6-26	1320-1322	to	_
6-27	1323-1331	monetary	_
6-28	1332-1342	incentives	_
6-29	1343-1345	in	_
6-30	1346-1353	chronic	_
6-31	1354-1358	pain	_
6-32	1359-1367	patients	_
6-33	1368-1371	who	_
6-34	1372-1376	take	_
6-35	1377-1384	opioids	_
6-36	1385-1391	versus	_
6-37	1392-1397	those	_
6-38	1398-1401	who	_
6-39	1402-1404	do	_
6-40	1405-1408	not	_
6-41	1409-1410	.	_

7-1	1411-1418	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
7-2	1419-1431	Participants	_
7-3	1432-1444	Thirty-seven	_
7-4	1445-1452	females	_
7-5	1453-1457	with	http://maven.renci.org/NeuroBridge/neurobridge#DiffusePain
7-6	1458-1470	fibromyalgia	http://maven.renci.org/NeuroBridge/neurobridge#DiffusePain
7-7	1471-1474	and	_
7-8	1475-1477	17	_
7-9	1478-1485	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-10	1486-1493	females	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-11	1494-1506	participated	_
7-12	1507-1509	in	_
7-13	1510-1513	the	_
7-14	1514-1519	study	_
7-15	1520-1521	.	_

8-1	1522-1525	All	_
8-2	1526-1538	fibromyalgia	_
8-3	1539-1551	participants	_
8-4	1552-1555	met	_
8-5	1556-1559	the	_
8-6	1560-1569	following	_
8-7	1570-1579	inclusion	_
8-8	1580-1588	criteria	_
8-9	1589-1590	:	_
8-10	1591-1599	American	_
8-11	1600-1607	College	_
8-12	1608-1610	of	_
8-13	1611-1623	Rheumatology	_
8-14	1624-1625	(	_
8-15	1626-1629	ACR	_
8-16	1630-1631	)	_
8-17	1632-1636	2011	_
8-18	1637-1645	criteria	_
8-19	1646-1649	for	_
8-20	1650-1662	fibromyalgia	_
8-21	1663-1664	[	_
8-22	1665-1666	(	_
8-23	1667-1668	1	_
8-24	1669-1670	)	_
8-25	1671-1681	widespread	_
8-26	1682-1686	pain	_
8-27	1687-1692	index	_
8-28	1693-1694	(	_
8-29	1695-1698	WPI	_
8-30	1699-1700	)	_
8-31	1701-1706	score	_
8-32	1707-1708	≥	_
8-33	1709-1710	7	_
8-34	1711-1712	+	_
8-35	1713-1720	symptom	_
8-36	1721-1729	severity	_
8-37	1730-1731	(	_
8-38	1732-1734	SS	_
8-39	1735-1736	)	_
8-40	1737-1742	score	_
8-41	1743-1744	≥	_
8-42	1745-1746	5	_
8-43	1747-1748	,	_
8-44	1749-1751	or	_
8-45	1752-1755	WPI	_
8-46	1756-1761	score	_
8-47	1762-1765	3–6	_
8-48	1766-1767	+	_
8-49	1768-1770	SS	_
8-50	1771-1776	score	_
8-51	1777-1778	≥	_
8-52	1779-1780	9	_
8-53	1781-1782	,	_
8-54	1783-1784	(	_
8-55	1785-1786	2	_
8-56	1787-1788	)	_
8-57	1789-1796	similar	_
8-58	1797-1802	level	_
8-59	1803-1805	of	_
8-60	1806-1814	symptoms	_
8-61	1815-1822	present	_
8-62	1823-1826	for	_
8-63	1827-1829	at	_
8-64	1830-1835	least	_
8-65	1836-1837	3	_
8-66	1838-1844	months	_
8-67	1845-1846	,	_
8-68	1847-1848	(	_
8-69	1849-1850	3	_
8-70	1851-1852	)	_
8-71	1853-1855	no	_
8-72	1856-1864	disorder	_
8-73	1865-1867	to	_
8-74	1868-1877	otherwise	_
8-75	1878-1885	explain	_
8-76	1886-1889	the	_
8-77	1890-1894	pain	_
8-78	1895-1896	]	_
8-79	1897-1898	,	_
8-80	1899-1903	pain	_
8-81	1904-1906	in	_
8-82	1907-1908	4	_
8-83	1909-1913	body	_
8-84	1914-1923	quadrants	_
8-85	1924-1925	,	_
8-86	1926-1934	previous	_
8-87	1935-1940	month	_
8-88	1941-1948	average	_
8-89	1949-1953	pain	_
8-90	1954-1959	score	_
8-91	1960-1962	of	_
8-92	1963-1965	at	_
8-93	1966-1971	least	_
8-94	1972-1973	2	_
8-95	1974-1975	(	_
8-96	1976-1980	0–10	_
8-97	1981-1987	verbal	_
8-98	1988-1993	scale	_
8-99	1994-1995	)	_
8-100	1996-1997	,	_
8-101	1998-2001	not	_
8-102	2002-2010	pregnant	_
8-103	2011-2013	or	_
8-104	2014-2021	nursing	_
8-105	2022-2023	,	_
8-106	2024-2026	no	_
8-107	2027-2030	MRI	_
8-108	2031-2048	contraindications	_
8-109	2049-2050	(	_
8-110	2051-2055	e.g.	_
8-111	2056-2057	,	_
8-112	2058-2072	claustrophobia	_
8-113	2073-2074	,	_
8-114	2075-2080	metal	_
8-115	2081-2083	in	_
8-116	2084-2088	body	_
8-117	2089-2090	)	_
8-118	2091-2092	,	_
8-119	2093-2096	and	_
8-120	2097-2099	no	_
8-121	2100-2112	uncontrolled	_
8-122	2113-2123	depression	_
8-123	2124-2126	or	_
8-124	2127-2134	anxiety	_
8-125	2135-2136	.	_

9-1	2137-2140	All	_
9-2	2141-2153	fibromyalgia	_
9-3	2154-2166	participants	_
9-4	2167-2171	were	_
9-5	2172-2179	allowed	_
9-6	2180-2182	to	_
9-7	2183-2191	continue	_
9-8	2192-2197	their	_
9-9	2198-2204	normal	_
9-10	2205-2208	use	_
9-11	2209-2211	of	_
9-12	2212-2223	medications	_
9-13	2224-2230	during	_
9-14	2231-2234	the	_
9-15	2235-2240	study	_
9-16	2241-2242	.	_

10-1	2243-2245	To	_
10-2	2246-2248	be	_
10-3	2249-2257	included	_
10-4	2258-2260	in	_
10-5	2261-2264	the	_
10-6	2265-2275	non-opioid	_
10-7	2276-2288	fibromyalgia	_
10-8	2289-2294	group	_
10-9	2295-2296	,	_
10-10	2297-2308	individuals	_
10-11	2309-2313	were	_
10-12	2314-2317	not	_
10-13	2318-2320	to	_
10-14	2321-2323	be	_
10-15	2324-2330	taking	_
10-16	2331-2338	opioids	_
10-17	2339-2341	as	_
10-18	2342-2346	part	_
10-19	2347-2349	of	_
10-20	2350-2355	their	_
10-21	2356-2365	treatment	_
10-22	2366-2367	,	_
10-23	2368-2371	not	_
10-24	2372-2374	to	_
10-25	2375-2379	have	_
10-26	2380-2385	taken	_
10-27	2386-2389	any	_
10-28	2390-2397	opioids	_
10-29	2398-2404	during	_
10-30	2405-2408	the	_
10-31	2409-2411	90	_
10-32	2412-2416	days	_
10-33	2417-2422	prior	_
10-34	2423-2425	to	_
10-35	2426-2431	study	_
10-36	2432-2445	participation	_
10-37	2446-2447	,	_
10-38	2448-2451	and	_
10-39	2452-2457	never	_
10-40	2458-2460	to	_
10-41	2461-2465	have	_
10-42	2466-2471	taken	_
10-43	2472-2479	opioids	_
10-44	2480-2483	for	_
10-45	2484-2485	a	_
10-46	2486-2492	period	_
10-47	2493-2500	greater	_
10-48	2501-2505	than	_
10-49	2506-2508	30	_
10-50	2509-2513	days	_
10-51	2514-2515	.	_

11-1	2516-2518	To	_
11-2	2519-2521	be	_
11-3	2522-2530	included	_
11-4	2531-2533	in	_
11-5	2534-2537	the	_
11-6	2538-2544	opioid	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
11-7	2545-2557	fibromyalgia	http://maven.renci.org/NeuroBridge/neurobridge#OpioidAbuse
11-8	2558-2563	group	_
11-9	2564-2565	,	_
11-10	2566-2577	individuals	_
11-11	2578-2582	were	_
11-12	2583-2591	required	_
11-13	2592-2594	to	_
11-14	2595-2597	be	_
11-15	2598-2602	have	_
11-16	2603-2607	been	_
11-17	2608-2614	taking	_
11-18	2615-2621	opioid	_
11-19	2622-2633	medications	_
11-20	2634-2636	as	_
11-21	2637-2641	part	_
11-22	2642-2644	of	_
11-23	2645-2650	their	_
11-24	2651-2660	treatment	_
11-25	2661-2664	for	_
11-26	2665-2667	at	_
11-27	2668-2673	least	_
11-28	2674-2675	3	_
11-29	2676-2682	months	_
11-30	2683-2686	and	_
11-31	2687-2689	at	_
11-32	2690-2693	the	_
11-33	2694-2698	time	_
11-34	2699-2701	of	_
11-35	2702-2707	study	_
11-36	2708-2721	participation	_
11-37	2722-2723	.	_

12-1	2724-2731	Control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
12-2	2732-2744	participants	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
12-3	2745-2749	were	_
12-4	2750-2758	required	_
12-5	2759-2761	to	_
12-6	2762-2765	not	_
12-7	2766-2770	have	_
12-8	2771-2778	chronic	_
12-9	2779-2783	pain	_
12-10	2784-2785	,	_
12-11	2786-2789	not	_
12-12	2790-2792	be	_
12-13	2793-2801	pregnant	_
12-14	2802-2804	or	_
12-15	2805-2812	nursing	_
12-16	2813-2814	,	_
12-17	2815-2819	have	_
12-18	2820-2822	no	_
12-19	2823-2826	MRI	_
12-20	2827-2844	contraindications	_
12-21	2845-2846	,	_
12-22	2847-2850	and	_
12-23	2851-2855	have	_
12-24	2856-2858	no	_
12-25	2859-2869	depression	_
12-26	2870-2872	or	_
12-27	2873-2880	anxiety	_
12-28	2881-2882	.	_

13-1	2883-2888	Study	_
13-2	2889-2899	procedures	_
13-3	2900-2903	All	_
13-4	2904-2914	procedures	_
13-5	2915-2919	were	_
13-6	2920-2928	approved	_
13-7	2929-2931	by	_
13-8	2932-2935	the	_
13-9	2936-2944	Stanford	_
13-10	2945-2955	University	_
13-11	2956-2969	Institutional	_
13-12	2970-2976	Review	_
13-13	2977-2982	Board	_
13-14	2983-2984	,	_
13-15	2985-2989	were	_
13-16	2990-2997	carried	_
13-17	2998-3001	out	_
13-18	3002-3004	in	_
13-19	3005-3015	accordance	_
13-20	3016-3020	with	_
13-21	3021-3024	the	_
13-22	3025-3033	approved	_
13-23	3034-3043	protocols	_
13-24	3044-3045	,	_
13-25	3046-3049	and	_
13-26	3050-3054	were	_
13-27	3055-3064	conducted	_
13-28	3065-3067	at	_
13-29	3068-3071	the	_
13-30	3072-3080	Stanford	_
13-31	3081-3091	University	_
13-32	3092-3099	Richard	_
13-33	3100-3102	M.	_
13-34	3103-3108	Lucas	_
13-35	3109-3115	Center	_
13-36	3116-3119	for	_
13-37	3120-3127	Imaging	_
13-38	3128-3129	.	_

14-1	3130-3133	All	_
14-2	3134-3146	participants	_
14-3	3147-3153	signed	_
14-4	3154-3161	written	_
14-5	3162-3165	and	_
14-6	3166-3174	informed	_
14-7	3175-3182	consent	_
14-8	3183-3196	acknowledging	_
14-9	3197-3202	their	_
14-10	3203-3214	willingness	_
14-11	3215-3217	to	_
14-12	3218-3229	participate	_
14-13	3230-3232	in	_
14-14	3233-3236	the	_
14-15	3237-3242	study	_
14-16	3243-3244	,	_
14-17	3245-3258	understanding	_
14-18	3259-3261	of	_
14-19	3262-3265	all	_
14-20	3266-3271	study	_
14-21	3272-3282	procedures	_
14-22	3283-3284	,	_
14-23	3285-3288	and	_
14-24	3289-3302	understanding	_
14-25	3303-3307	that	_
14-26	3308-3312	they	_
14-27	3313-3317	were	_
14-28	3318-3322	free	_
14-29	3323-3325	to	_
14-30	3326-3334	withdraw	_
14-31	3335-3340	their	_
14-32	3341-3346	study	_
14-33	3347-3360	participation	_
14-34	3361-3363	at	_
14-35	3364-3367	any	_
14-36	3368-3372	time	_
14-37	3373-3374	.	_

15-1	3375-3379	Data	_
15-2	3380-3384	from	_
15-3	3385-3388	the	_
15-4	3389-3396	control	_
15-5	3397-3400	and	_
15-6	3401-3411	non-opioid	_
15-7	3412-3424	fibromyalgia	_
15-8	3425-3431	groups	_
15-9	3432-3436	were	_
15-10	3437-3445	analyzed	_
15-11	3446-3456	previously	_
15-12	3457-3460	and	_
15-13	3461-3469	included	_
15-14	3470-3472	in	_
15-15	3473-3480	another	_
15-16	3481-3492	publication	_
15-17	3493-3494	.	_

16-1	3495-3500	Prior	_
16-2	3501-3503	to	_
16-3	3504-3507	the	_
16-4	3508-3512	scan	_
16-5	3513-3520	session	_
16-6	3521-3522	,	_
16-7	3523-3528	study	_
16-8	3529-3541	participants	_
16-9	3542-3550	received	_
16-10	3551-3562	instruction	_
16-11	3563-3566	and	_
16-12	3567-3576	practiced	_
16-13	3577-3580	the	_
16-14	3581-3584	MID	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
16-15	3585-3589	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
16-16	3590-3591	(	_
16-17	3592-3595	for	_
16-18	3596-3609	approximately	_
16-19	3610-3611	5	_
16-20	3612-3619	minutes	_
16-21	3620-3621	)	_
16-22	3622-3625	and	_
16-23	3626-3629	use	_
16-24	3630-3632	of	_
16-25	3633-3640	arousal	http://maven.renci.org/NeuroBridge/neurobridge#Continuous
16-26	3641-3644	and	_
16-27	3645-3652	valence	_
16-28	3653-3659	rating	_
16-29	3660-3666	scales	_
16-30	3667-3668	.	_

17-1	3669-3671	If	_
17-2	3672-3681	necessary	_
17-3	3682-3683	,	_
17-4	3684-3687	the	_
17-5	3688-3691	MID	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
17-6	3692-3696	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
17-7	3697-3705	practice	_
17-8	3706-3709	was	_
17-9	3710-3718	repeated	_
17-10	3719-3724	until	_
17-11	3725-3728	the	_
17-12	3729-3740	participant	_
17-13	3741-3751	understood	_
17-14	3752-3755	the	_
17-15	3756-3760	task	_
17-16	3761-3764	and	_
17-17	3765-3774	performed	_
17-18	3775-3778	the	_
17-19	3779-3783	task	_
17-20	3784-3796	successfully	_
17-21	3797-3798	.	_

18-1	3799-3811	Participants	_
18-2	3812-3821	underwent	_
18-3	3822-3830	training	_
18-4	3831-3833	on	_
18-5	3834-3837	the	_
18-6	3838-3844	rating	_
18-7	3845-3851	scales	_
18-8	3852-3855	for	_
18-9	3856-3863	arousal	_
18-10	3864-3867	and	_
18-11	3868-3875	valence	_
18-12	3876-3880	with	_
18-13	3881-3888	written	_
18-14	3889-3901	instructions	_
18-15	3902-3911	presented	_
18-16	3912-3914	on	_
18-17	3915-3916	a	_
18-18	3917-3923	laptop	_
18-19	3924-3927	and	_
18-20	3928-3937	explained	_
18-21	3938-3940	to	_
18-22	3941-3953	participants	_
18-23	3954-3956	by	_
18-24	3957-3964	trained	_
18-25	3965-3974	personnel	_
18-26	3975-3976	.	_

19-1	3977-3991	Questionnaires	_
19-2	3992-3996	were	_
19-3	3997-4009	administered	_
19-4	4010-4012	to	_
19-5	4013-4016	all	_
19-6	4017-4025	subjects	_
19-7	4026-4028	to	_
19-8	4029-4038	determine	_
19-9	4039-4047	clinical	_
19-10	4048-4051	and	_
19-11	4052-4065	psychological	_
19-12	4066-4074	measures	_
19-13	4075-4080	among	_
19-14	4081-4084	the	_
19-15	4085-4088	two	_
19-16	4089-4101	fibromyalgia	_
19-17	4102-4108	groups	_
19-18	4109-4112	and	_
19-19	4113-4120	control	_
19-20	4121-4126	group	_
19-21	4127-4128	.	_

20-1	4129-4143	Questionnaires	_
20-2	4144-4152	measured	_
20-3	4153-4163	depression	_
20-4	4164-4165	,	_
20-5	4166-4173	anxiety	_
20-6	4174-4175	,	_
20-7	4176-4186	behavioral	_
20-8	4187-4206	inhibition/approach	_
20-9	4207-4208	,	_
20-10	4209-4213	mood	_
20-11	4214-4215	,	_
20-12	4216-4224	positive	_
20-13	4225-4228	and	_
20-14	4229-4237	negative	_
20-15	4238-4244	affect	_
20-16	4245-4246	,	_
20-17	4247-4251	pain	_
20-18	4252-4264	distribution	_
20-19	4265-4266	,	_
20-20	4267-4271	pain	_
20-21	4272-4281	intensity	_
20-22	4282-4283	,	_
20-23	4284-4288	pain	_
20-24	4289-4301	interference	_
20-25	4302-4303	,	_
20-26	4304-4308	pain	_
20-27	4309-4321	distribution	_
20-28	4322-4323	,	_
20-29	4324-4327	and	_
20-30	4328-4335	fatigue	_
20-31	4336-4337	(	_
20-32	4338-4341	see	_
20-33	4342-4347	Table	_
20-34	4348-4349	2	_
20-35	4350-4353	and	_
20-36	4354-4367	Supplementary	_
20-37	4368-4375	Methods	_
20-38	4376-4379	for	_
20-39	4380-4381	a	_
20-40	4382-4386	list	_
20-41	4387-4390	and	_
20-42	4391-4401	references	_
20-43	4402-4405	for	_
20-44	4406-4420	questionnaires	_
20-45	4421-4429	included	_
20-46	4430-4432	in	_
20-47	4433-4436	the	_
20-48	4437-4445	analysis	_
20-49	4446-4447	)	_
20-50	4448-4449	.	_

21-1	4450-4460	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
21-2	4461-4464	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
21-3	4465-4468	and	_
21-4	4469-4473	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
21-5	4474-4478	data	_
21-6	4479-4483	were	_
21-7	4484-4492	acquired	_
21-8	4493-4497	from	_
21-9	4498-4501	all	_
21-10	4502-4514	participants	_
21-11	4515-4520	using	_
21-12	4521-4522	a	_
21-13	4523-4525	3T	_
21-14	4526-4533	General	_
21-15	4534-4542	Electric	_
21-16	4543-4550	scanner	_
21-17	4551-4556	using	_
21-18	4557-4559	an	_
21-19	4560-4569	8-channel	_
21-20	4570-4574	head	_
21-21	4575-4579	coil	_
21-22	4580-4581	(	_
21-23	4582-4584	GE	_
21-24	4585-4592	Systems	_
21-25	4593-4594	,	_
21-26	4595-4602	Chicago	_
21-27	4603-4604	,	_
21-28	4605-4613	Illinois	_
21-29	4614-4615	)	_
21-30	4616-4617	.	_

22-1	4618-4621	The	_
22-2	4622-4626	scan	_
22-3	4627-4634	session	_
22-4	4635-4644	consisted	_
22-5	4645-4647	of	_
22-6	4648-4649	a	_
22-7	4650-4659	localizer	_
22-8	4660-4664	scan	http://maven.renci.org/NeuroBridge/neurobridge#ComputedTomographyScan
22-9	4665-4666	,	_
22-10	4667-4672	asset	_
22-11	4673-4684	calibration	_
22-12	4685-4690	scans	_
22-13	4691-4692	,	_
22-14	4693-4694	2	_
22-15	4695-4698	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
22-16	4699-4703	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
22-17	4704-4708	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
22-18	4709-4714	scans	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
22-19	4715-4716	,	_
22-20	4717-4720	and	_
22-21	4721-4722	a	_
22-22	4723-4725	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
22-23	4726-4736	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
22-24	4737-4741	scan	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
22-25	4742-4743	.	_

23-1	4744-4747	The	_
23-2	4748-4749	2	_
23-3	4750-4753	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
23-4	4754-4758	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
23-5	4759-4763	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
23-6	4764-4769	scans	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
23-7	4770-4774	were	_
23-8	4775-4783	acquired	_
23-9	4784-4796	sequentially	_
23-10	4797-4798	(	_
23-11	4799-4801	no	_
23-12	4802-4807	break	_
23-13	4808-4810	in	_
23-14	4811-4818	between	_
23-15	4819-4820	)	_
23-16	4821-4824	and	_
23-17	4825-4829	with	_
23-18	4830-4833	the	_
23-19	4834-4843	following	_
23-20	4844-4854	parameters	_
23-21	4855-4856	:	_
23-22	4857-4865	Gradient	_
23-23	4866-4870	Echo	_
23-24	4871-4876	Pulse	_
23-25	4877-4885	Sequence	_
23-26	4886-4890	with	_
23-27	4891-4897	spiral	_
23-28	4898-4904	in-out	_
23-29	4905-4916	acquisition	_
23-30	4917-4918	,	_
23-31	4919-4923	flip	_
23-32	4924-4929	angle	_
23-33	4930-4932	of	_
23-34	4933-4936	76°	_
23-35	4937-4938	,	_
23-36	4939-4943	echo	_
23-37	4944-4948	time	_
23-38	4949-4950	(	_
23-39	4951-4953	TE	_
23-40	4954-4955	)	_
23-41	4956-4958	of	_
23-42	4959-4961	30	_
23-43	4962-4969	seconds	_
23-44	4970-4971	,	_
23-45	4972-4982	repetition	_
23-46	4983-4987	time	_
23-47	4988-4989	(	_
23-48	4990-4992	TR	_
23-49	4993-4994	)	_
23-50	4995-4997	of	_
23-51	4998-4999	2	_
23-52	5000-5007	seconds	_
23-53	5008-5009	,	_
23-54	5010-5020	sequential	_
23-55	5021-5031	descending	_
23-56	5032-5037	slice	_
23-57	5038-5043	order	_
23-58	5044-5045	,	_
23-59	5046-5048	32	_
23-60	5049-5056	oblique	_
23-61	5057-5063	slices	_
23-62	5064-5065	,	_
23-63	5066-5071	slice	_
23-64	5072-5081	thickness	_
23-65	5082-5083	4	_
23-66	5084-5086	mm	_
23-67	5087-5088	,	_
23-68	5089-5092	gap	_
23-69	5093-5096	0.5	_
23-70	5097-5099	mm	_
23-71	5100-5101	,	_
23-72	5102-5107	pixel	_
23-73	5108-5112	size	_
23-74	5113-5117	3.43	_
23-75	5118-5120	mm	_
23-76	5121-5122	.	_

24-1	5123-5126	The	_
24-2	5127-5133	spiral	_
24-3	5134-5140	in-out	_
24-4	5141-5145	scan	_
24-5	5146-5154	sequence	_
24-6	5155-5158	was	_
24-7	5159-5163	used	_
24-8	5164-5171	because	_
24-9	5172-5174	it	_
24-10	5175-5182	reduces	_
24-11	5183-5196	orbitofrontal	_
24-12	5197-5203	signal	_
24-13	5204-5212	drop-out	_
24-14	5213-5216	and	_
24-15	5217-5225	improves	_
24-16	5226-5237	acquisition	_
24-17	5238-5240	of	_
24-18	5241-5244	the	_
24-19	5245-5251	medial	_
24-20	5252-5262	prefrontal	_
24-21	5263-5269	cortex	_
24-22	5270-5273	and	_
24-23	5274-5287	orbitofrontal	_
24-24	5288-5294	cortex	_
24-25	5295-5296	.	_

25-1	5297-5300	The	_
25-2	5301-5304	MID	_
25-3	5305-5306	1	_
25-4	5307-5311	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
25-5	5312-5316	scan	_
25-6	5317-5325	included	_
25-7	5326-5329	266	_
25-8	5330-5337	volumes	_
25-9	5338-5341	and	_
25-10	5342-5345	the	_
25-11	5346-5349	MID	_
25-12	5350-5351	2	_
25-13	5352-5356	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
25-14	5357-5361	scan	_
25-15	5362-5370	included	_
25-16	5371-5374	302	_
25-17	5375-5382	volumes	_
25-18	5383-5384	,	_
25-19	5385-5394	excluding	_
25-20	5395-5397	12	_
25-21	5398-5399	s	_
25-22	5400-5407	lead-in	_
25-23	5408-5411	and	_
25-24	5412-5413	8	_
25-25	5414-5415	s	_
25-26	5416-5424	lead-out	_
25-27	5425-5426	.	_

26-1	5427-5430	The	_
26-2	5431-5433	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
26-3	5434-5444	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
26-4	5445-5449	scan	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
26-5	5450-5453	was	_
26-6	5454-5462	acquired	_
26-7	5463-5468	using	_
26-8	5469-5471	3D	_
26-9	5472-5477	FSPGR	_
26-10	5478-5479	(	_
26-11	5480-5484	fast	_
26-12	5485-5492	spoiled	_
26-13	5493-5506	gradient-echo	_
26-14	5507-5508	)	_
26-15	5509-5515	IRprep	_
26-16	5516-5521	BRAVO	_
26-17	5522-5525	for	_
26-18	5526-5538	registration	_
26-19	5539-5541	of	_
26-20	5542-5552	functional	_
26-21	5553-5559	images	_
26-22	5560-5563	and	_
26-23	5564-5572	included	_
26-24	5573-5578	whole	_
26-25	5579-5584	brain	_
26-26	5585-5586	,	_
26-27	5587-5596	brainstem	_
26-28	5597-5600	and	_
26-29	5601-5611	cerebellum	_
26-30	5612-5620	coverage	_
26-31	5621-5622	;	_
26-32	5623-5628	slice	_
26-33	5629-5638	thickness	_
26-34	5639-5640	1	_
26-35	5641-5643	mm	_
26-36	5644-5645	;	_
26-37	5646-5655	frequency	_
26-38	5656-5661	field	_
26-39	5662-5664	of	_
26-40	5665-5669	view	_
26-41	5670-5671	(	_
26-42	5672-5675	FOV	_
26-43	5676-5677	)	_
26-44	5678-5680	22	_
26-45	5681-5683	mm	_
26-46	5684-5685	,	_
26-47	5686-5704	anterior/posterior	_
26-48	5705-5714	frequency	_
26-49	5715-5724	direction	_
26-50	5725-5726	,	_
26-51	5727-5728	2	_
26-52	5729-5735	number	_
26-53	5736-5738	of	_
26-54	5739-5750	excitations	_
26-55	5751-5752	(	_
26-56	5753-5756	NEX	_
26-57	5757-5758	)	_
26-58	5759-5760	,	_
26-59	5761-5764	11°	_
26-60	5765-5769	flip	_
26-61	5770-5775	angle	_
26-62	5776-5777	,	_
26-63	5778-5781	6.8	_
26-64	5782-5784	TR	_
26-65	5785-5786	,	_
26-66	5787-5790	2.6	_
26-67	5791-5793	TE	_
26-68	5794-5795	,	_
26-69	5796-5799	256	_
26-70	5800-5809	frequency	_
26-71	5810-5811	,	_
26-72	5812-5815	256	_
26-73	5816-5821	phase	_
26-74	5822-5823	,	_
26-75	5824-5829	50.00	_
26-76	5830-5839	bandwidth	_
26-77	5840-5841	.	_

27-1	5842-5850	Monetary	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
27-2	5851-5860	Incentive	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
27-3	5861-5866	Delay	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
27-4	5867-5868	(	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
27-5	5869-5872	MID	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
27-6	5873-5874	)	http://maven.renci.org/NeuroBridge/neurobridge#DegenerativeDiseaseoftheCentralNervousSystem
27-7	5875-5879	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
27-8	5880-5884	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
27-9	5885-5887	We	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
27-10	5888-5891	ran	_
27-11	5892-5895	the	_
27-12	5896-5899	MID	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
27-13	5900-5904	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
27-14	5905-5907	in	_
27-15	5908-5914	MATLAB	_
27-16	5915-5916	(	_
27-17	5917-5923	MATLAB	_
27-18	5924-5930	R2012b	_
27-19	5931-5932	,	_
27-20	5933-5942	MathWorks	_
27-21	5943-5944	,	_
27-22	5945-5951	Natick	_
27-23	5952-5953	,	_
27-24	5954-5956	MA	_
27-25	5957-5958	)	_
27-26	5959-5960	,	_
27-27	5961-5966	using	_
27-28	5967-5980	Psychophysics	_
27-29	5981-5988	Toolbox	_
27-30	5989-5992	for	_
27-31	5993-6005	presentation	_
27-32	6006-6008	of	_
27-33	6009-6015	visual	_
27-34	6016-6023	stimuli	_
27-35	6024-6025	(	_
27-36	6026-6040	Psychtoolbox-3	_
27-37	6041-6042	)	_
27-38	6043-6046	via	_
27-39	6047-6048	a	_
27-40	6049-6055	screen	_
27-41	6056-6062	placed	_
27-42	6063-6068	above	_
27-43	6069-6072	the	_
27-44	6073-6084	participant	_
27-45	6085-6087	in	_
27-46	6088-6091	the	_
27-47	6092-6099	scanner	_
27-48	6100-6101	.	_

28-1	6102-6113	Participant	_
28-2	6114-6123	responses	_
28-3	6124-6126	to	_
28-4	6127-6130	the	_
28-5	6131-6135	task	_
28-6	6136-6140	were	_
28-7	6141-6150	collected	_
28-8	6151-6156	using	_
28-9	6157-6158	a	_
28-10	6159-6165	custom	_
28-11	6166-6174	designed	_
28-12	6175-6181	button	_
28-13	6182-6185	box	_
28-14	6186-6187	.	_

29-1	6188-6189	A	_
29-2	6190-6195	total	_
29-3	6196-6198	of	_
29-4	6199-6201	90	_
29-5	6202-6208	trials	_
29-6	6209-6213	were	_
29-7	6214-6226	administered	_
29-8	6227-6233	during	_
29-9	6234-6237	the	_
29-10	6238-6241	two	_
29-11	6242-6245	MID	_
29-12	6246-6250	task	_
29-13	6251-6256	scans	_
29-14	6257-6259	as	_
29-15	6260-6269	performed	_
29-16	6270-6280	previously	_
29-17	6281-6282	.	_

30-1	6283-6287	Cues	_
30-2	6288-6297	indicated	_
30-3	6298-6301	the	_
30-4	6302-6308	amount	_
30-5	6309-6311	of	_
30-6	6312-6317	money	_
30-7	6318-6320	to	_
30-8	6321-6323	be	_
30-9	6324-6335	potentially	_
30-10	6336-6342	gained	_
30-11	6343-6344	(	_
30-12	6345-6346	+	_
30-13	6347-6348	$	_
30-14	6349-6353	5.00	_
30-15	6354-6355	,	_
30-16	6356-6357	+	_
30-17	6358-6359	$	_
30-18	6360-6364	1.00	_
30-19	6365-6366	,	_
30-20	6367-6368	+	_
30-21	6369-6370	$	_
30-22	6371-6375	0.00	_
30-23	6376-6377	)	_
30-24	6378-6380	or	_
30-25	6381-6385	lost	_
30-26	6386-6387	(	_
30-27	6388-6389	−	_
30-28	6390-6391	$	_
30-29	6392-6396	5.00	_
30-30	6397-6398	,	_
30-31	6399-6400	−	_
30-32	6401-6402	$	_
30-33	6403-6407	1.00	_
30-34	6408-6409	,	_
30-35	6410-6411	−	_
30-36	6412-6413	$	_
30-37	6414-6418	0.00	_
30-38	6419-6420	)	_
30-39	6421-6427	during	_
30-40	6428-6432	each	_
30-41	6433-6438	trial	_
30-42	6439-6440	.	_

31-1	6441-6446	After	_
31-2	6447-6448	a	_
31-3	6449-6450	2	_
31-4	6451-6452	s	_
31-5	6453-6458	delay	_
31-6	6459-6460	(	_
31-7	6461-6469	fixation	_
31-8	6470-6475	cross	_
31-9	6476-6477	)	_
31-10	6478-6479	a	_
31-11	6480-6486	target	_
31-12	6487-6488	(	_
31-13	6489-6497	triangle	_
31-14	6498-6499	)	_
31-15	6500-6503	was	_
31-16	6504-6513	presented	_
31-17	6514-6515	.	_

32-1	6516-6528	Participants	_
32-2	6529-6535	needed	_
32-3	6536-6538	to	_
32-4	6539-6547	initiate	_
32-5	6548-6549	a	_
32-6	6550-6558	response	_
32-7	6559-6560	(	_
32-8	6561-6567	button	_
32-9	6568-6573	press	_
32-10	6574-6575	)	_
32-11	6576-6578	to	_
32-12	6579-6585	either	_
32-13	6586-6589	win	_
32-14	6590-6591	(	_
32-15	6592-6600	positive	_
32-16	6601-6605	cues	_
32-17	6606-6607	)	_
32-18	6608-6610	or	_
32-19	6611-6616	avoid	_
32-20	6617-6623	losing	_
32-21	6624-6625	(	_
32-22	6626-6634	negative	_
32-23	6635-6639	cues	_
32-24	6640-6641	)	_
32-25	6642-6645	the	_
32-26	6646-6652	amount	_
32-27	6653-6658	shown	_
32-28	6659-6660	.	_

33-1	6661-6671	Successful	_
33-2	6672-6681	responses	_
33-3	6682-6683	(	_
33-4	6684-6688	i.e.	_
33-5	6689-6690	,	_
33-6	6691-6700	occurring	_
33-7	6701-6706	prior	_
33-8	6707-6709	to	_
33-9	6710-6716	target	_
33-10	6717-6725	duration	_
33-11	6726-6732	offset	_
33-12	6733-6734	)	_
33-13	6735-6744	generated	_
33-14	6745-6746	a	_
33-15	6747-6748	“	_
33-16	6749-6752	hit	_
33-17	6753-6754	”	_
33-18	6755-6758	and	_
33-19	6759-6771	unsuccessful	_
33-20	6772-6781	responses	_
33-21	6782-6791	generated	_
33-22	6792-6793	a	_
33-23	6794-6795	“	_
33-24	6796-6800	miss	_
33-25	6801-6802	”	_
33-26	6803-6804	.	_

34-1	6805-6813	Outcomes	_
34-2	6814-6817	for	_
34-3	6818-6822	each	_
34-4	6823-6828	trial	_
34-5	6829-6833	were	_
34-6	6834-6843	presented	_
34-7	6844-6846	as	_
34-8	6847-6850	the	_
34-9	6851-6857	amount	_
34-10	6858-6864	gained	_
34-11	6865-6866	(	_
34-12	6867-6871	e.g.	_
34-13	6872-6873	,	_
34-14	6874-6875	+	_
34-15	6876-6877	$	_
34-16	6878-6882	5.00	_
34-17	6883-6884	)	_
34-18	6885-6886	,	_
34-19	6887-6890	not	_
34-20	6891-6897	gained	_
34-21	6898-6899	(	_
34-22	6900-6901	+	_
34-23	6902-6903	$	_
34-24	6904-6908	0.00	_
34-25	6909-6910	)	_
34-26	6911-6912	,	_
34-27	6913-6916	not	_
34-28	6917-6921	lost	_
34-29	6922-6923	(	_
34-30	6924-6925	−	_
34-31	6926-6927	$	_
34-32	6928-6932	0.00	_
34-33	6933-6934	)	_
34-34	6935-6936	,	_
34-35	6937-6939	or	_
34-36	6940-6944	lost	_
34-37	6945-6946	(	_
34-38	6947-6951	e.g.	_
34-39	6952-6953	,	_
34-40	6954-6955	−	_
34-41	6956-6957	$	_
34-42	6958-6962	5.00	_
34-43	6963-6964	)	_
34-44	6965-6966	.	_

35-1	6967-6973	Target	_
35-2	6974-6983	durations	_
35-3	6984-6990	varied	_
35-4	6991-6992	:	_
35-5	6993-7000	initial	_
35-6	7001-7007	target	_
35-7	7008-7017	durations	_
35-8	7018-7022	were	_
35-9	7023-7026	set	_
35-10	7027-7029	at	_
35-11	7030-7033	the	_
35-12	7034-7043	beginning	_
35-13	7044-7046	of	_
35-14	7047-7050	the	_
35-15	7051-7055	scan	_
35-16	7056-7057	(	_
35-17	7058-7067	typically	_
35-18	7068-7071	250	_
35-19	7072-7074	ms	_
35-20	7075-7076	)	_
35-21	7077-7080	and	_
35-22	7081-7097	programmatically	_
35-23	7098-7106	adjusted	_
35-24	7107-7117	throughout	_
35-25	7118-7121	the	_
35-26	7122-7126	task	_
35-27	7127-7129	to	_
35-28	7130-7136	target	_
35-29	7137-7138	“	_
35-30	7139-7142	hit	_
35-31	7143-7144	”	_
35-32	7145-7149	rate	_
35-33	7150-7152	of	_
35-34	7153-7166	approximately	_
35-35	7167-7169	66	_
35-36	7170-7171	%	_
35-37	7172-7178	across	_
35-38	7179-7185	trials	_
35-39	7186-7187	.	_

36-1	7188-7195	Arousal	_
36-2	7196-7197	(	_
36-3	7198-7213	low-medium-high	_
36-4	7214-7215	)	_
36-5	7216-7219	and	_
36-6	7220-7227	valence	_
36-7	7228-7229	(	_
36-8	7230-7255	negative-neutral-positive	_
36-9	7256-7257	)	_
36-10	7258-7265	ratings	_
36-11	7266-7270	were	_
36-12	7271-7280	collected	_
36-13	7281-7286	after	_
36-14	7287-7290	the	_
36-15	7291-7294	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
36-16	7295-7299	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
36-17	7300-7304	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
36-18	7305-7310	scans	_
36-19	7311-7316	using	_
36-20	7317-7324	7-point	_
36-21	7325-7331	Likert	_
36-22	7332-7338	scales	_
36-23	7339-7340	.	_

37-1	7341-7353	Participants	_
37-2	7354-7358	were	_
37-3	7359-7363	sent	_
37-4	7364-7370	Amazon	_
37-5	7371-7381	electronic	_
37-6	7382-7386	gift	_
37-7	7387-7392	cards	_
37-8	7393-7396	for	_
37-9	7397-7400	the	_
37-10	7401-7409	combined	_
37-11	7410-7415	total	_
37-12	7416-7418	of	_
37-13	7419-7424	gains	_
37-14	7425-7428	and	_
37-15	7429-7435	losses	_
37-16	7436-7442	during	_
37-17	7443-7446	the	_
37-18	7447-7451	task	_
37-19	7452-7457	after	_
37-20	7458-7468	completion	_
37-21	7469-7471	of	_
37-22	7472-7475	the	_
37-23	7476-7480	scan	_
37-24	7481-7482	.	_

38-1	7483-7487	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
38-2	7488-7492	Data	_
38-3	7493-7506	preprocessing	_
38-4	7507-7519	Neuroimaging	_
38-5	7520-7524	data	_
38-6	7525-7529	were	_
38-7	7530-7542	preprocessed	_
38-8	7543-7548	using	_
38-9	7549-7553	AFNI	_
38-10	7554-7562	software	_
38-11	7563-7564	(	_
38-12	7565-7573	Analysis	_
38-13	7574-7576	of	_
38-14	7577-7587	Functional	_
38-15	7588-7599	Neuroimages	_
38-16	7600-7601	)	_
38-17	7602-7603	[	_
38-18	7604-7615	precompiled	_
38-19	7616-7622	binary	_
38-20	7623-7643	macosx_10.7_Intel_64	_
38-21	7644-7645	:	_
38-22	7646-7649	Jun	_
38-23	7650-7652	10	_
38-24	7653-7657	2016	_
38-25	7658-7659	(	_
38-26	7660-7667	Version	_
38-27	7668-7680	AFNI_16.1.21	_
38-28	7681-7682	)	_
38-29	7683-7684	]	_
38-30	7685-7690	using	_
38-31	7691-7697	custom	_
38-32	7698-7705	scripts	_
38-33	7706-7707	,	_
38-34	7708-7711	and	_
38-35	7712-7714	as	_
38-36	7715-7724	performed	_
38-37	7725-7735	previously	_
38-38	7736-7737	.	_

39-1	7738-7743	First	_
39-2	7744-7745	,	_
39-3	7746-7747	6	_
39-4	7748-7755	read-in	_
39-5	7756-7759	and	_
39-6	7760-7761	9	_
39-7	7762-7770	read-out	_
39-8	7771-7778	volumes	_
39-9	7779-7783	were	_
39-10	7784-7792	excluded	_
39-11	7793-7797	from	_
39-12	7798-7801	the	_
39-13	7802-7806	scan	_
39-14	7807-7811	data	_
39-15	7812-7813	,	_
39-16	7814-7817	the	_
39-17	7818-7819	2	_
39-18	7820-7823	MID	_
39-19	7824-7828	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
39-20	7829-7834	scans	_
39-21	7835-7839	were	_
39-22	7840-7844	then	_
39-23	7845-7857	concatenated	_
39-24	7858-7862	into	_
39-25	7863-7866	one	_
39-26	7867-7873	series	_
39-27	7874-7876	of	_
39-28	7877-7883	images	_
39-29	7884-7885	.	_

40-1	7886-7890	Next	_
40-2	7891-7892	,	_
40-3	7893-7896	the	_
40-4	7897-7907	functional	_
40-5	7908-7914	images	_
40-6	7915-7919	were	_
40-7	7920-7925	slice	_
40-8	7926-7930	time	_
40-9	7931-7940	corrected	_
40-10	7941-7942	,	_
40-11	7943-7954	transformed	_
40-12	7955-7959	from	_
40-13	7960-7967	oblique	_
40-14	7968-7970	to	_
40-15	7971-7976	axial	_
40-16	7977-7982	slice	_
40-17	7983-7994	orientation	_
40-18	7995-7996	,	_
40-19	7997-8000	and	_
40-20	8001-8008	aligned	_
40-21	8009-8013	with	_
40-22	8014-8017	the	_
40-23	8018-8028	structural	_
40-24	8029-8035	images	_
40-25	8036-8037	.	_

41-1	8038-8044	Motion	_
41-2	8045-8055	correction	_
41-3	8056-8059	was	_
41-4	8060-8069	performed	_
41-5	8070-8074	with	_
41-6	8075-8076	6	_
41-7	8077-8084	degrees	_
41-8	8085-8087	of	_
41-9	8088-8096	movement	_
41-10	8097-8098	[	_
41-11	8099-8110	translation	_
41-12	8111-8112	(	_
41-13	8113-8114	x	_
41-14	8115-8116	,	_
41-15	8117-8118	y	_
41-16	8119-8120	,	_
41-17	8121-8122	z	_
41-18	8123-8124	)	_
41-19	8125-8126	,	_
41-20	8127-8135	rotation	_
41-21	8136-8137	(	_
41-22	8138-8142	roll	_
41-23	8143-8144	,	_
41-24	8145-8150	pitch	_
41-25	8151-8152	,	_
41-26	8153-8156	yaw	_
41-27	8157-8158	)	_
41-28	8159-8160	]	_
41-29	8161-8162	.	_

42-1	8163-8166	The	_
42-2	8167-8177	functional	_
42-3	8178-8184	images	_
42-4	8185-8189	were	_
42-5	8190-8199	spatially	_
42-6	8200-8208	smoothed	_
42-7	8209-8214	using	_
42-8	8215-8216	a	_
42-9	8217-8218	4	_
42-10	8219-8221	mm	_
42-11	8222-8223	(	_
42-12	8224-8234	full-width	_
42-13	8235-8247	half-maximum	_
42-14	8248-8249	,	_
42-15	8250-8254	FWHM	_
42-16	8255-8256	)	_
42-17	8257-8265	Gaussian	_
42-18	8266-8272	kernel	_
42-19	8273-8274	.	_

43-1	8275-8284	Intensity	_
43-2	8285-8298	normalization	_
43-3	8299-8302	was	_
43-4	8303-8310	applied	_
43-5	8311-8313	by	_
43-6	8314-8325	calculating	_
43-7	8326-8329	the	_
43-8	8330-8337	percent	_
43-9	8338-8344	signal	_
43-10	8345-8351	change	_
43-11	8352-8355	per	_
43-12	8356-8361	voxel	_
43-13	8362-8365	and	_
43-14	8366-8374	division	_
43-15	8375-8377	by	_
43-16	8378-8381	the	_
43-17	8382-8389	average	_
43-18	8390-8391	.	_

44-1	8392-8394	We	_
44-2	8395-8402	applied	_
44-3	8403-8404	a	_
44-4	8405-8410	0.011	_
44-5	8411-8413	Hz	_
44-6	8414-8423	high-pass	_
44-7	8424-8430	filter	_
44-8	8431-8433	to	_
44-9	8434-8437	the	_
44-10	8438-8448	functional	_
44-11	8449-8453	data	_
44-12	8454-8455	.	_

45-1	8456-8466	Structural	_
45-2	8467-8473	images	_
45-3	8474-8478	were	_
45-4	8479-8485	warped	_
45-5	8486-8488	to	_
45-6	8489-8498	Talairach	_
45-7	8499-8504	space	_
45-8	8505-8508	and	_
45-9	8509-8519	functional	_
45-10	8520-8526	images	_
45-11	8527-8531	were	_
45-12	8532-8538	warped	_
45-13	8539-8541	to	_
45-14	8542-8545	the	_
45-15	8546-8555	Talairach	_
45-16	8556-8562	warped	_
45-17	8563-8573	structural	_
45-18	8574-8580	images	_
45-19	8581-8582	.	_

46-1	8583-8584	A	_
46-2	8585-8590	white	_
46-3	8591-8597	matter	_
46-4	8598-8599	(	_
46-5	8600-8602	WM	_
46-6	8603-8604	)	_
46-7	8605-8608	and	_
46-8	8609-8610	a	_
46-9	8611-8624	cerebrospinal	_
46-10	8625-8630	fluid	_
46-11	8631-8632	(	_
46-12	8633-8636	CSF	_
46-13	8637-8638	)	_
46-14	8639-8643	mask	_
46-15	8644-8648	were	_
46-16	8649-8656	created	_
46-17	8657-8660	for	_
46-18	8661-8665	each	_
46-19	8666-8673	subject	_
46-20	8674-8675	’	_
46-21	8676-8677	s	_
46-22	8678-8688	functional	_
46-23	8689-8694	image	_
46-24	8695-8700	based	_
46-25	8701-8703	on	_
46-26	8704-8710	signal	_
46-27	8711-8720	intensity	_
46-28	8721-8723	in	_
46-29	8724-8728	seed	_
46-30	8729-8733	loci	_
46-31	8734-8736	in	_
46-32	8737-8739	WM	_
46-33	8740-8743	and	_
46-34	8744-8747	CSF	_
46-35	8748-8755	regions	_
46-36	8756-8757	,	_
46-37	8758-8770	respectively	_
46-38	8771-8772	.	_

47-1	8773-8777	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
47-2	8778-8782	Task	_
47-3	8783-8792	contrasts	_
47-4	8793-8795	As	_
47-5	8796-8800	used	_
47-6	8801-8811	previously	_
47-7	8812-8816	four	_
47-8	8817-8825	separate	_
47-9	8826-8836	orthogonal	_
47-10	8837-8847	regressors	_
47-11	8848-8858	contrasted	_
47-12	8859-8868	responses	_
47-13	8869-8871	to	_
47-14	8872-8876	gain	_
47-15	8877-8880	and	_
47-16	8881-8885	loss	_
47-17	8886-8892	during	_
47-18	8893-8905	anticipation	_
47-19	8906-8909	and	_
47-20	8910-8917	outcome	_
47-21	8918-8919	:	_
47-22	8920-8924	gain	_
47-23	8925-8931	versus	_
47-24	8932-8939	no-gain	_
47-25	8940-8952	anticipation	_
47-26	8953-8954	(	_
47-27	8955-8961	GVNant	_
47-28	8962-8963	)	_
47-29	8964-8965	,	_
47-30	8966-8970	loss	_
47-31	8971-8977	versus	_
47-32	8978-8985	no-loss	_
47-33	8986-8998	anticipation	_
47-34	8999-9000	(	_
47-35	9001-9007	LVNant	_
47-36	9008-9009	)	_
47-37	9010-9011	,	_
47-38	9012-9016	gain	_
47-39	9017-9023	versus	_
47-40	9024-9031	no-gain	_
47-41	9032-9039	outcome	_
47-42	9040-9041	(	_
47-43	9042-9048	GVNout	_
47-44	9049-9050	)	_
47-45	9051-9052	,	_
47-46	9053-9056	and	_
47-47	9057-9064	no-loss	_
47-48	9065-9071	versus	_
47-49	9072-9076	loss	_
47-50	9077-9084	outcome	_
47-51	9085-9086	(	_
47-52	9087-9093	NVLout	_
47-53	9094-9095	)	_
47-54	9096-9097	.	_

48-1	9098-9107	Contrasts	_
48-2	9108-9116	compared	_
48-3	9117-9121	gain	_
48-4	9122-9125	and	_
48-5	9126-9130	loss	_
48-6	9131-9141	conditions	_
48-7	9142-9144	to	_
48-8	9145-9152	neutral	_
48-9	9153-9154	(	_
48-10	9155-9159	i.e.	_
48-11	9160-9161	,	_
48-12	9162-9165	+/−	_
48-13	9166-9167	$	_
48-14	9168-9169	0	_
48-15	9170-9171	)	_
48-16	9172-9182	conditions	_
48-17	9183-9184	,	_
48-18	9185-9191	rather	_
48-19	9192-9196	than	_
48-20	9197-9199	to	_
48-21	9200-9201	a	_
48-22	9202-9213	no-stimulus	_
48-23	9214-9222	baseline	_
48-24	9223-9232	condition	_
48-25	9233-9234	,	_
48-26	9235-9237	in	_
48-27	9238-9243	order	_
48-28	9244-9246	to	_
48-29	9247-9248	(	_
48-30	9249-9250	1	_
48-31	9251-9252	)	_
48-32	9253-9258	focus	_
48-33	9259-9261	on	_
48-34	9262-9273	differences	_
48-35	9274-9276	in	_
48-36	9277-9289	reward/value	_
48-37	9290-9299	processes	_
48-38	9300-9302	in	_
48-39	9303-9306	the	_
48-40	9307-9312	brain	_
48-41	9313-9316	and	_
48-42	9317-9318	(	_
48-43	9319-9320	2	_
48-44	9321-9322	)	_
48-45	9323-9325	to	_
48-46	9326-9333	exclude	_
48-47	9334-9341	general	_
48-48	9342-9361	performance-related	_
48-49	9362-9367	brain	_
48-50	9368-9376	activity	_
48-51	9377-9381	from	_
48-52	9382-9385	the	_
48-53	9386-9395	evaluated	_
48-54	9396-9402	signal	_
48-55	9403-9404	.	_

49-1	9405-9417	Specifically	_
49-2	9418-9419	,	_
49-3	9420-9423	the	_
49-4	9424-9433	contrasts	_
49-5	9434-9442	included	_
49-6	9443-9444	:	_
49-7	9445-9451	GVNant	_
49-8	9452-9453	:	_
49-9	9454-9466	anticipation	_
49-10	9467-9473	during	_
49-11	9474-9483	potential	_
49-12	9484-9488	gain	_
49-13	9489-9490	(	_
49-14	9491-9492	+	_
49-15	9493-9494	$	_
49-16	9495-9496	5	_
49-17	9497-9500	cue	_
49-18	9501-9502	)	_
49-19	9503-9509	trials	_
49-20	9510-9516	versus	_
49-21	9517-9529	anticipation	_
49-22	9530-9536	during	_
49-23	9537-9546	potential	_
49-24	9547-9554	no-gain	_
49-25	9555-9556	(	_
49-26	9557-9560	+/−	_
49-27	9561-9562	$	_
49-28	9563-9564	0	_
49-29	9565-9568	cue	_
49-30	9569-9570	)	_
49-31	9571-9577	trials	_
49-32	9578-9579	;	_
49-33	9580-9586	LVNant	_
49-34	9587-9588	:	_
49-35	9589-9601	anticipation	_
49-36	9602-9608	during	_
49-37	9609-9618	potential	_
49-38	9619-9623	loss	_
49-39	9624-9625	(	_
49-40	9626-9627	−	_
49-41	9628-9629	$	_
49-42	9630-9631	5	_
49-43	9632-9635	cue	_
49-44	9636-9637	)	_
49-45	9638-9644	trials	_
49-46	9645-9651	versus	_
49-47	9652-9664	anticipation	_
49-48	9665-9671	during	_
49-49	9672-9681	potential	_
49-50	9682-9689	no-loss	_
49-51	9690-9691	(	_
49-52	9692-9695	+/−	_
49-53	9696-9697	$	_
49-54	9698-9699	0	_
49-55	9700-9703	cue	_
49-56	9704-9705	)	_
49-57	9706-9712	trials	_
49-58	9713-9714	;	_
49-59	9715-9721	GVNout	_
49-60	9722-9723	:	_
49-61	9724-9727	hit	_
49-62	9728-9729	(	_
49-63	9730-9731	+	_
49-64	9732-9733	$	_
49-65	9734-9735	5	_
49-66	9736-9743	outcome	_
49-67	9744-9745	)	_
49-68	9746-9752	versus	_
49-69	9753-9757	miss	_
49-70	9758-9759	(	_
49-71	9760-9761	+	_
49-72	9762-9763	$	_
49-73	9764-9765	0	_
49-74	9766-9773	outcome	_
49-75	9774-9775	)	_
49-76	9776-9782	during	_
49-77	9783-9786	the	_
49-78	9787-9794	outcome	_
49-79	9795-9801	period	_
49-80	9802-9805	for	_
49-81	9806-9815	potential	_
49-82	9816-9820	gain	_
49-83	9821-9822	(	_
49-84	9823-9824	+	_
49-85	9825-9826	$	_
49-86	9827-9828	5	_
49-87	9829-9832	cue	_
49-88	9833-9834	)	_
49-89	9835-9841	trials	_
49-90	9842-9843	;	_
49-91	9844-9850	NVLout	_
49-92	9851-9852	:	_
49-93	9853-9856	hit	_
49-94	9857-9858	(	_
49-95	9859-9860	−	_
49-96	9861-9862	$	_
49-97	9863-9864	0	_
49-98	9865-9872	outcome	_
49-99	9873-9874	)	_
49-100	9875-9881	versus	_
49-101	9882-9886	miss	_
49-102	9887-9888	(	_
49-103	9889-9890	−	_
49-104	9891-9892	$	_
49-105	9893-9894	5	_
49-106	9895-9902	outcome	_
49-107	9903-9904	)	_
49-108	9905-9911	during	_
49-109	9912-9915	the	_
49-110	9916-9923	outcome	_
49-111	9924-9930	period	_
49-112	9931-9934	for	_
49-113	9935-9944	potential	_
49-114	9945-9949	loss	_
49-115	9950-9951	(	_
49-116	9952-9953	−	_
49-117	9954-9955	$	_
49-118	9956-9957	5	_
49-119	9958-9961	cue	_
49-120	9962-9963	)	_
49-121	9964-9970	trials	_
49-122	9971-9972	.	_

50-1	9973-9976	The	_
50-2	9977-9987	regressors	_
50-3	9988-9990	of	_
50-4	9991-9999	interest	_
50-5	10000-10004	were	_
50-6	10005-10014	convolved	_
50-7	10015-10019	with	_
50-8	10020-10021	a	_
50-9	10022-10028	single	_
50-10	10029-10034	gamma	_
50-11	10035-10043	function	_
50-12	10044-10057	approximating	_
50-13	10058-10061	the	_
50-14	10062-10073	hemodynamic	_
50-15	10074-10082	response	_
50-16	10083-10084	,	_
50-17	10085-10089	with	_
50-18	10090-10103	approximately	_
50-19	10104-10105	a	_
50-20	10106-10107	6	_
50-21	10108-10114	second	_
50-22	10115-10120	delay	_
50-23	10121-10122	.	_

51-1	10123-10125	We	_
51-2	10126-10133	applied	_
51-3	10134-10146	conservative	_
51-4	10147-10153	motion	_
51-5	10154-10163	censoring	_
51-6	10164-10166	to	_
51-7	10167-10170	the	_
51-8	10171-10181	regressors	_
51-9	10182-10184	so	_
51-10	10185-10189	that	_
51-11	10190-10193	any	_
51-12	10194-10200	volume	_
51-13	10201-10208	showing	_
51-14	10209-10215	motion	_
51-15	10216-10223	greater	_
51-16	10224-10228	than	_
51-17	10229-10232	0.5	_
51-18	10233-10235	mm	_
51-19	10236-10237	(	_
51-20	10238-10241	and	_
51-21	10242-10251	preceding	_
51-22	10252-10258	volume	_
51-23	10259-10260	)	_
51-24	10261-10265	were	_
51-25	10266-10274	excluded	_
51-26	10275-10276	.	_

52-1	10277-10286	Resulting	_
52-2	10287-10297	activation	_
52-3	10298-10302	maps	_
52-4	10303-10304	“	_
52-5	10305-10313	activity	_
52-6	10314-10315	”	_
52-7	10316-10319	for	_
52-8	10320-10324	each	_
52-9	10325-10336	participant	_
52-10	10337-10348	represented	_
52-11	10349-10354	blood	_
52-12	10355-10366	oxygenation	_
52-13	10367-10372	level	_
52-14	10373-10382	dependent	_
52-15	10383-10384	(	_
52-16	10385-10389	BOLD	_
52-17	10390-10391	)	_
52-18	10392-10398	signal	_
52-19	10399-10400	(	_
52-20	10401-10402	a	_
52-21	10403-10412	correlate	_
52-22	10413-10415	of	_
52-23	10416-10421	blood	_
52-24	10422-10433	oxygenation	_
52-25	10434-10440	levels	_
52-26	10441-10446	which	_
52-27	10447-10450	are	_
52-28	10451-10452	a	_
52-29	10453-10462	correlate	_
52-30	10463-10465	of	_
52-31	10466-10472	neural	_
52-32	10473-10481	activity	_
52-33	10482-10484	in	_
52-34	10485-10489	fMRI	_
52-35	10490-10491	)	_
52-36	10492-10500	response	_
52-37	10501-10514	corresponding	_
52-38	10515-10517	to	_
52-39	10518-10521	the	_
52-40	10522-10531	regressor	_
52-41	10532-10535	for	_
52-42	10536-10540	each	_
52-43	10541-10549	contrast	_
52-44	10550-10560	separately	_
52-45	10561-10562	.	_

53-1	10563-10568	These	_
53-2	10569-10579	individual	_
53-3	10580-10590	activation	_
53-4	10591-10595	maps	_
53-5	10596-10600	were	_
53-6	10601-10607	tested	_
53-7	10608-10611	for	_
53-8	10612-10617	group	_
53-9	10618-10629	differences	_
53-10	10630-10636	within	_
53-11	10637-10638	a	_
53-12	10639-10645	priori	_
53-13	10646-10650	ROIs	_
53-14	10651-10654	and	_
53-15	10655-10663	post-hoc	_
53-16	10664-10669	whole	_
53-17	10670-10675	brain	_
53-18	10676-10681	group	_
53-19	10682-10693	comparisons	_
53-20	10694-10695	.	_

54-1	10696-10698	To	_
54-2	10699-10707	maximize	_
54-3	10708-10711	our	_
54-4	10712-10719	chances	_
54-5	10720-10722	of	_
54-6	10723-10734	identifying	_
54-7	10735-10746	significant	_
54-8	10747-10752	group	_
54-9	10753-10760	effects	_
54-10	10761-10764	and	_
54-11	10765-10775	consistent	_
54-12	10776-10780	with	_
54-13	10781-10791	previously	_
54-14	10792-10801	published	_
54-15	10802-10809	methods	_
54-16	10810-10811	,	_
54-17	10812-10818	trials	_
54-18	10819-10823	with	_
54-19	10824-10825	+	_
54-20	10826-10827	$	_
54-21	10828-10829	1	_
54-22	10830-10834	cues	_
54-23	10835-10839	were	_
54-24	10840-10848	excluded	_
54-25	10849-10853	from	_
54-26	10854-10857	the	_
54-27	10858-10862	fMRI	_
54-28	10863-10872	contrasts	_
54-29	10873-10880	because	_
54-30	10881-10884	the	_
54-31	10885-10893	strength	_
54-32	10894-10896	of	_
54-33	10897-10901	BOLD	_
54-34	10902-10908	signal	_
54-35	10909-10917	response	_
54-36	10918-10921	for	_
54-37	10922-10927	these	_
54-38	10928-10934	trials	_
54-39	10935-10938	was	_
54-40	10939-10949	determined	_
54-41	10950-10952	to	_
54-42	10953-10955	be	_
54-43	10956-10960	much	_
54-44	10961-10966	lower	_
54-45	10967-10971	than	_
54-46	10972-10978	trials	_
54-47	10979-10983	with	_
54-48	10984-10985	+	_
54-49	10986-10987	$	_
54-50	10988-10989	5	_
54-51	10990-10994	cues	_
54-52	10995-10996	(	_
54-53	10997-11010	Supplementary	_
54-54	11011-11014	Fig	_
54-55	11015-11016	.	_

55-1	11017-11019	S5	_
55-2	11020-11021	)	_
55-3	11022-11023	.	_

56-1	11024-11030	Region	_
56-2	11031-11033	of	_
56-3	11034-11042	Interest	_
56-4	11043-11047	fMRI	_
56-5	11048-11056	analyses	_
56-6	11057-11063	Region	_
56-7	11064-11066	of	_
56-8	11067-11075	interest	_
56-9	11076-11077	(	_
56-10	11078-11081	ROI	_
56-11	11082-11083	)	_
56-12	11084-11092	analyses	_
56-13	11093-11100	focused	_
56-14	11101-11103	on	_
56-15	11104-11107	the	_
56-16	11108-11112	NAcc	_
56-17	11113-11116	and	_
56-18	11117-11121	MPFC	_
56-19	11122-11123	.	_

57-1	11124-11126	We	_
57-2	11127-11136	predicted	_
57-3	11137-11141	that	_
57-4	11142-11143	,	_
57-5	11144-11146	in	_
57-6	11147-11157	comparison	_
57-7	11158-11160	to	_
57-8	11161-11165	both	_
57-9	11166-11173	control	_
57-10	11174-11177	and	_
57-11	11178-11188	non-opioid	_
57-12	11189-11201	fibromyalgia	_
57-13	11202-11203	,	_
57-14	11204-11207	the	_
57-15	11208-11214	opioid	_
57-16	11215-11227	fibromyalgia	_
57-17	11228-11233	group	_
57-18	11234-11239	would	_
57-19	11240-11244	show	_
57-20	11245-11246	:	_
57-21	11247-11248	1	_
57-22	11249-11250	)	_
57-23	11251-11260	decreased	_
57-24	11261-11265	NAcc	_
57-25	11266-11274	activity	_
57-26	11275-11281	during	_
57-27	11282-11286	gain	_
57-28	11287-11299	anticipation	_
57-29	11300-11301	(	_
57-30	11302-11308	GVNant	_
57-31	11309-11310	)	_
57-32	11311-11314	and	_
57-33	11315-11322	no-loss	_
57-34	11323-11330	outcome	_
57-35	11331-11332	(	_
57-36	11333-11339	NVLout	_
57-37	11340-11341	)	_
57-38	11342-11343	,	_
57-39	11344-11345	2	_
57-40	11346-11347	)	_
57-41	11348-11357	decreased	_
57-42	11358-11362	MPFC	_
57-43	11363-11371	activity	_
57-44	11372-11378	during	_
57-45	11379-11383	gain	_
57-46	11384-11396	anticipation	_
57-47	11397-11398	(	_
57-48	11399-11405	GVNant	_
57-49	11406-11407	)	_
57-50	11408-11409	,	_
57-51	11410-11413	and	_
57-52	11414-11415	3	_
57-53	11416-11417	)	_
57-54	11418-11427	increased	_
57-55	11428-11432	MPFC	_
57-56	11433-11441	activity	_
57-57	11442-11448	during	_
57-58	11449-11456	no-loss	_
57-59	11457-11464	outcome	_
57-60	11465-11466	(	_
57-61	11467-11473	NVLout	_
57-62	11474-11475	)	_
57-63	11476-11477	.	_

58-1	11478-11480	We	_
58-2	11481-11488	created	_
58-3	11489-11492	the	_
58-4	11493-11502	bilateral	_
58-5	11503-11507	NAcc	_
58-6	11508-11511	ROI	_
58-7	11512-11514	by	_
58-8	11515-11524	combining	_
58-9	11525-11528	the	_
58-10	11529-11533	left	_
58-11	11534-11537	and	_
58-12	11538-11543	right	_
58-13	11544-11553	accumbens	_
58-14	11554-11561	regions	_
58-15	11562-11566	from	_
58-16	11567-11570	the	_
58-17	11571-11576	Desai	_
58-18	11577-11582	Atlas	_
58-19	11583-11584	(	_
58-20	11585-11589	AFNI	_
58-21	11590-11591	)	_
58-22	11592-11595	and	_
58-23	11596-11606	resampling	_
58-24	11607-11609	to	_
58-25	11610-11620	functional	_
58-26	11621-11626	image	_
58-27	11627-11637	resolution	_
58-28	11638-11639	(	_
58-29	11640-11642	52	_
58-30	11643-11649	voxels	_
58-31	11650-11651	;	_
58-32	11652-11657	voxel	_
58-33	11658-11662	size	_
58-34	11663-11664	=	_
58-35	11665-11668	2.9	_
58-36	11669-11671	mm	_
58-37	11672-11673	×	_
58-38	11674-11677	2.9	_
58-39	11678-11680	mm	_
58-40	11681-11682	×	_
58-41	11683-11686	2.9	_
58-42	11687-11689	mm	_
58-43	11690-11691	)	_
58-44	11692-11693	.	_

59-1	11694-11696	We	_
59-2	11697-11704	created	_
59-3	11705-11708	the	_
59-4	11709-11718	bilateral	_
59-5	11719-11723	MPFC	_
59-6	11724-11727	ROI	_
59-7	11728-11730	by	_
59-8	11731-11738	drawing	_
59-9	11739-11742	two	_
59-10	11743-11752	conjoined	_
59-11	11753-11754	4	_
59-12	11755-11757	mm	_
59-13	11758-11764	radius	_
59-14	11765-11772	spheres	_
59-15	11773-11774	(	_
59-16	11775-11779	+/−4	_
59-17	11780-11781	,	_
59-18	11782-11784	50	_
59-19	11785-11786	,	_
59-20	11787-11789	−3	_
59-21	11790-11791	)	_
59-22	11792-11798	within	_
59-23	11799-11807	Brodmann	_
59-24	11808-11812	Area	_
59-25	11813-11815	10	_
59-26	11816-11829	corresponding	_
59-27	11830-11833	the	_
59-28	11834-11841	frontal	_
59-29	11842-11846	pole	_
59-30	11847-11850	and	_
59-31	11851-11861	resampling	_
59-32	11862-11864	to	_
59-33	11865-11875	functional	_
59-34	11876-11881	image	_
59-35	11882-11892	resolution	_
59-36	11893-11894	(	_
59-37	11895-11897	42	_
59-38	11898-11904	voxels	_
59-39	11905-11906	)	_
59-40	11907-11908	.	_

60-1	11909-11919	Additional	_
60-2	11920-11931	information	_
60-3	11932-11941	regarding	_
60-4	11942-11945	the	_
60-5	11946-11953	precise	_
60-6	11954-11963	selection	_
60-7	11964-11966	of	_
60-8	11967-11970	the	_
60-9	11971-11975	MPFC	_
60-10	11976-11979	ROI	_
60-11	11980-11983	can	_
60-12	11984-11986	be	_
60-13	11987-11992	found	_
60-14	11993-11995	in	_
60-15	11996-11999	the	_
60-16	12000-12013	Supplementary	_
60-17	12014-12021	Methods	_
60-18	12022-12023	.	_

61-1	12024-12026	We	_
61-2	12027-12036	extracted	_
61-3	12037-12041	fMRI	_
61-4	12042-12048	values	_
61-5	12049-12053	from	_
61-6	12054-12059	these	_
61-7	12060-12064	ROIs	_
61-8	12065-12068	and	_
61-9	12069-12078	performed	_
61-10	12079-12084	group	_
61-11	12085-12096	statistical	_
61-12	12097-12108	comparisons	_
61-13	12109-12114	using	_
61-14	12115-12123	analysis	_
61-15	12124-12126	of	_
61-16	12127-12135	variance	_
61-17	12136-12137	(	_
61-18	12138-12143	ANOVA	_
61-19	12144-12145	)	_
61-20	12146-12149	and	_
61-21	12150-12158	post-hoc	_
61-22	12159-12166	t-tests	_
61-23	12167-12169	in	_
61-24	12170-12174	SPSS	_
61-25	12175-12176	(	_
61-26	12177-12180	IBM	_
61-27	12181-12185	SPSS	_
61-28	12186-12196	Statistics	_
61-29	12197-12200	for	_
61-30	12201-12210	Macintosh	_
61-31	12211-12212	,	_
61-32	12213-12220	Version	_
61-33	12221-12225	22.0	_
61-34	12226-12227	.	_

62-1	12228-12234	Armonk	_
62-2	12235-12236	,	_
62-3	12237-12239	NY	_
62-4	12240-12241	)	_
62-5	12242-12243	.	_

63-1	12244-12254	Additional	_
63-2	12255-12266	correlation	_
63-3	12267-12275	analyses	_
63-4	12276-12280	were	_
63-5	12281-12290	performed	_
63-6	12291-12298	between	_
63-7	12299-12302	the	_
63-8	12303-12306	ROI	_
63-9	12307-12311	data	_
63-10	12312-12315	and	_
63-11	12316-12326	behavioral	_
63-12	12327-12330	and	_
63-13	12331-12339	clinical	_
63-14	12340-12348	measures	_
63-15	12349-12354	using	_
63-16	12355-12359	SPSS	_
63-17	12360-12361	.	_

64-1	12362-12370	Clinical	_
64-2	12371-12374	and	_
64-3	12375-12388	psychological	_
64-4	12389-12393	data	_
64-5	12394-12402	analysis	_
64-6	12403-12416	Questionnaire	_
64-7	12417-12421	data	_
64-8	12422-12426	were	_
64-9	12427-12437	quantified	_
64-10	12438-12441	for	_
64-11	12442-12446	each	_
64-12	12447-12460	questionnaire	_
64-13	12461-12471	separately	_
64-14	12472-12475	and	_
64-15	12476-12480	then	_
64-16	12481-12489	assessed	_
64-17	12490-12493	for	_
64-18	12494-12499	group	_
64-19	12500-12511	differences	_
64-20	12512-12517	using	_
64-21	12518-12523	ANOVA	_
64-22	12524-12525	(	_
64-23	12526-12530	SPSS	_
64-24	12531-12532	)	_
64-25	12533-12534	.	_

65-1	12535-12543	Post-hoc	_
65-2	12544-12551	between	_
65-3	12552-12557	group	_
65-4	12558-12565	t-tests	_
65-5	12566-12570	were	_
65-6	12571-12575	then	_
65-7	12576-12580	used	_
65-8	12581-12583	to	_
65-9	12584-12593	determine	_
65-10	12594-12605	differences	_
65-11	12606-12613	between	_
65-12	12614-12624	individual	_
65-13	12625-12631	groups	_
65-14	12632-12633	(	_
65-15	12634-12639	Tukey	_
65-16	12640-12641	,	_
65-17	12642-12646	SPSS	_
65-18	12647-12648	)	_
65-19	12649-12650	.	_

66-1	12651-12652	(	_
66-2	12653-12656	See	_
66-3	12657-12662	Table	_
66-4	12663-12664	2	_
66-5	12665-12668	and	_
66-6	12669-12682	Supplementary	_
66-7	12683-12690	Methods	_
66-8	12691-12694	for	_
66-9	12695-12699	list	_
66-10	12700-12703	and	_
66-11	12704-12716	descriptions	_
66-12	12717-12719	of	_
66-13	12720-12734	questionnaires	_
66-14	12735-12736	)	_
66-15	12737-12738	.	_

67-1	12739-12749	Behavioral	_
67-2	12750-12758	analysis	_
67-3	12759-12761	We	_
67-4	12762-12770	assessed	_
67-5	12771-12782	performance	_
67-6	12783-12786	and	_
67-7	12787-12797	behavioral	_
67-8	12798-12807	responses	_
67-9	12808-12810	to	_
67-10	12811-12814	the	_
67-11	12815-12818	MID	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
67-12	12819-12823	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
67-13	12824-12826	by	_
67-14	12827-12836	analyzing	_
67-15	12837-12845	accuracy	_
67-16	12846-12847	(	_
67-17	12848-12855	percent	_
67-18	12856-12859	hit	_
67-19	12860-12864	rate	_
67-20	12865-12866	)	_
67-21	12867-12868	,	_
67-22	12869-12877	reaction	_
67-23	12878-12883	times	_
67-24	12884-12885	,	_
67-25	12886-12889	and	_
67-26	12890-12899	post-task	_
67-27	12900-12907	ratings	_
67-28	12908-12910	of	_
67-29	12911-12918	arousal	_
67-30	12919-12922	and	_
67-31	12923-12930	valence	_
67-32	12931-12933	to	_
67-33	12934-12942	monetary	_
67-34	12943-12947	cues	_
67-35	12948-12949	.	_

68-1	12950-12962	Additionally	_
68-2	12963-12964	,	_
68-3	12965-12973	measures	_
68-4	12974-12976	of	_
68-5	12977-12985	positive	_
68-6	12986-12993	arousal	_
68-7	12994-12997	and	_
68-8	12998-13006	negative	_
68-9	13007-13014	arousal	_
68-10	13015-13019	were	_
68-11	13020-13030	calculated	_
68-12	13031-13035	from	_
68-13	13036-13049	mean-deviated	_
68-14	13050-13057	ratings	_
68-15	13058-13060	of	_
68-16	13061-13068	arousal	_
68-17	13069-13072	and	_
68-18	13073-13080	valence	_
68-19	13081-13087	within	_
68-20	13088-13096	subjects	_
68-21	13097-13099	as	_
68-22	13100-13104	done	_
68-23	13105-13115	previously	_
68-24	13116-13117	.	_

69-1	13118-13122	Each	_
69-2	13123-13125	of	_
69-3	13126-13131	these	_
69-4	13132-13140	measures	_
69-5	13141-13145	were	_
69-6	13146-13154	assessed	_
69-7	13155-13165	separately	_
69-8	13166-13169	for	_
69-9	13170-13181	differences	_
69-10	13182-13188	across	_
69-11	13189-13192	the	_
69-12	13193-13194	3	_
69-13	13195-13201	groups	_
69-14	13202-13207	using	_
69-15	13208-13209	a	_
69-16	13210-13217	two-way	_
69-17	13218-13223	ANOVA	_
69-18	13224-13228	with	_
69-19	13229-13236	factors	_
69-20	13237-13239	of	_
69-21	13240-13245	trial	_
69-22	13246-13247	(	_
69-23	13248-13252	here	_
69-24	13253-13254	,	_
69-25	13255-13256	“	_
69-26	13257-13262	trial	_
69-27	13263-13264	”	_
69-28	13265-13271	simply	_
69-29	13272-13278	refers	_
69-30	13279-13281	to	_
69-31	13282-13288	trials	_
69-32	13289-13293	with	_
69-33	13294-13303	different	_
69-34	13304-13308	cues	_
69-35	13309-13310	:	_
69-36	13311-13312	+	_
69-37	13313-13314	$	_
69-38	13315-13316	0	_
69-39	13317-13318	,	_
69-40	13319-13320	+	_
69-41	13321-13322	$	_
69-42	13323-13324	1	_
69-43	13325-13326	,	_
69-44	13327-13328	+	_
69-45	13329-13330	$	_
69-46	13331-13332	5	_
69-47	13333-13334	,	_
69-48	13335-13336	−	_
69-49	13337-13338	$	_
69-50	13339-13340	0	_
69-51	13341-13342	,	_
69-52	13343-13344	−	_
69-53	13345-13346	$	_
69-54	13347-13348	1	_
69-55	13349-13350	,	_
69-56	13351-13352	−	_
69-57	13353-13354	$	_
69-58	13355-13356	5	_
69-59	13357-13358	)	_
69-60	13359-13360	,	_
69-61	13361-13366	group	_
69-62	13367-13368	(	_
69-63	13369-13371	HC	_
69-64	13372-13373	,	_
69-65	13374-13377	FMN	_
69-66	13378-13379	,	_
69-67	13380-13383	FMO	_
69-68	13384-13385	)	_
69-69	13386-13387	,	_
69-70	13388-13391	and	_
69-71	13392-13397	trial	_
69-72	13398-13400	by	_
69-73	13401-13406	group	_
69-74	13407-13418	interaction	_
69-75	13419-13420	)	_
69-76	13421-13422	.	_

70-1	13423-13431	Post-hoc	_
70-2	13432-13439	one-way	_
70-3	13440-13445	ANOVA	_
70-4	13446-13451	tests	_
70-5	13452-13456	were	_
70-6	13457-13461	also	_
70-7	13462-13466	used	_
70-8	13467-13469	to	_
70-9	13470-13479	determine	_
70-10	13480-13485	group	_
70-11	13486-13493	effects	_
70-12	13494-13497	for	_
70-13	13498-13502	each	_
70-14	13503-13512	trial/cue	_
70-15	13513-13523	separately	_
70-16	13524-13525	(	_
70-17	13526-13532	MATLAB	_
70-18	13533-13534	,	_
70-19	13535-13541	R2017a	_
70-20	13542-13543	)	_
70-21	13544-13545	.	_

71-1	13546-13549	MID	_
71-2	13550-13554	Task	_
71-3	13555-13559	fMRI	_
71-4	13560-13568	analysis	_
71-5	13569-13577	Averaged	_
71-6	13578-13582	beta	_
71-7	13583-13589	values	_
71-8	13590-13591	(	_
71-9	13592-13601	parameter	_
71-10	13602-13611	estimates	_
71-11	13612-13613	)	_
71-12	13614-13618	were	_
71-13	13619-13628	extracted	_
71-14	13629-13632	for	_
71-15	13633-13637	each	_
71-16	13638-13641	ROI	_
71-17	13642-13646	from	_
71-18	13647-13651	each	_
71-19	13652-13663	participant	_
71-20	13664-13667	for	_
71-21	13668-13672	each	_
71-22	13673-13681	contrast	_
71-23	13682-13693	combination	_
71-24	13694-13699	using	_
71-25	13700-13706	custom	_
71-26	13707-13714	scripts	_
71-27	13715-13716	(	_
71-28	13717-13723	MATLAB	_
71-29	13724-13725	,	_
71-30	13726-13730	AFNI	_
71-31	13731-13732	)	_
71-32	13733-13734	.	_

72-1	13735-13738	The	_
72-2	13739-13748	extracted	_
72-3	13749-13753	beta	_
72-4	13754-13760	values	_
72-5	13761-13765	were	_
72-6	13766-13774	compared	_
72-7	13775-13780	among	_
72-8	13781-13787	groups	_
72-9	13788-13793	using	_
72-10	13794-13799	ANOVA	_
72-11	13800-13801	(	_
72-12	13802-13806	SPSS	_
72-13	13807-13808	)	_
72-14	13809-13810	.	_

73-1	13811-13813	We	_
73-2	13814-13817	set	_
73-3	13818-13821	the	_
73-4	13822-13834	significance	_
73-5	13835-13844	threshold	_
73-6	13845-13847	to	_
73-7	13848-13849	p	_
73-8	13850-13851	<	_
73-9	13852-13858	0.0125	_
73-10	13859-13860	(	_
73-11	13861-13868	initial	_
73-12	13869-13870	p	_
73-13	13871-13872	<	_
73-14	13873-13877	0.05	_
73-15	13878-13887	threshold	_
73-16	13888-13898	Bonferroni	_
73-17	13899-13908	corrected	_
73-18	13909-13912	for	_
73-19	13913-13914	4	_
73-20	13915-13928	predetermined	_
73-21	13929-13932	ROI	_
73-22	13933-13934	x	_
73-23	13935-13943	contrast	_
73-24	13944-13955	comparisons	_
73-25	13956-13957	:	_
73-26	13958-13962	NAcc	_
73-27	13963-13969	GVNant	_
73-28	13970-13971	,	_
73-29	13972-13976	NAcc	_
73-30	13977-13983	NVLout	_
73-31	13984-13985	,	_
73-32	13986-13990	MPFC	_
73-33	13991-13997	GVNant	_
73-34	13998-13999	,	_
73-35	14000-14004	MPFC	_
73-36	14005-14011	NVLout	_
73-37	14012-14013	)	_
73-38	14014-14015	.	_

74-1	14016-14028	Additionally	_
74-2	14029-14030	,	_
74-3	14031-14034	raw	_
74-4	14035-14039	time	_
74-5	14040-14046	course	_
74-6	14047-14051	data	_
74-7	14052-14056	were	_
74-8	14057-14064	plotted	_
74-9	14065-14067	by	_
74-10	14068-14078	extracting	_
74-11	14079-14083	each	_
74-12	14084-14095	participant	_
74-13	14096-14097	’	_
74-14	14098-14099	s	_
74-15	14100-14104	fMRI	_
74-16	14105-14109	data	_
74-17	14110-14111	,	_
74-18	14112-14119	sorting	_
74-19	14120-14122	by	_
74-20	14123-14128	trial	_
74-21	14129-14133	type	_
74-22	14134-14135	,	_
74-23	14136-14139	and	_
74-24	14140-14148	removing	_
74-25	14149-14156	volumes	_
74-26	14157-14161	with	_
74-27	14162-14168	signal	_
74-28	14169-14178	exceeding	_
74-29	14179-14180	>	_
74-30	14181-14182	4	_
74-31	14183-14191	standard	_
74-32	14192-14202	deviations	_
74-33	14203-14207	from	_
74-34	14208-14212	mean	_
74-35	14213-14221	activity	_
74-36	14222-14223	.	_

75-1	14224-14228	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
75-2	14229-14240	Correlation	_
75-3	14241-14249	analysis	_
75-4	14250-14262	Correlations	_
75-5	14263-14270	between	_
75-6	14271-14275	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
75-7	14276-14280	beta	_
75-8	14281-14287	values	_
75-9	14288-14289	(	_
75-10	14290-14294	NAcc	_
75-11	14295-14301	GVNant	_
75-12	14302-14303	,	_
75-13	14304-14308	NAcc	_
75-14	14309-14315	NVLout	_
75-15	14316-14317	,	_
75-16	14318-14322	MPFC	_
75-17	14323-14329	GVNant	_
75-18	14330-14331	,	_
75-19	14332-14335	and	_
75-20	14336-14340	MPFC	_
75-21	14341-14347	NVLout	_
75-22	14348-14349	)	_
75-23	14350-14353	and	_
75-24	14354-14367	questionnaire	_
75-25	14368-14377	variables	_
75-26	14378-14382	were	_
75-27	14383-14389	tested	_
75-28	14390-14396	across	_
75-29	14397-14400	the	_
75-30	14401-14404	two	_
75-31	14405-14417	fibromyalgia	_
75-32	14418-14424	groups	_
75-33	14425-14426	(	_
75-34	14427-14435	2-tailed	_
75-35	14436-14437	,	_
75-36	14438-14447	bivariate	_
75-37	14448-14449	,	_
75-38	14450-14457	Pearson	_
75-39	14458-14469	correlation	_
75-40	14470-14471	,	_
75-41	14472-14476	SPSS	_
75-42	14477-14478	)	_
75-43	14479-14480	(	_
75-44	14481-14484	see	_
75-45	14485-14498	Supplementary	_
75-46	14499-14506	Methods	_
75-47	14507-14510	for	_
75-48	14511-14515	list	_
75-49	14516-14518	of	_
75-50	14519-14527	included	_
75-51	14528-14542	questionnaires	_
75-52	14543-14544	)	_
75-53	14545-14546	.	_

76-1	14547-14559	Correlations	_
76-2	14560-14567	between	_
76-3	14568-14571	ROI	_
76-4	14572-14576	fMRI	_
76-5	14577-14581	beta	_
76-6	14582-14588	values	_
76-7	14589-14592	and	_
76-8	14593-14606	questionnaire	_
76-9	14607-14616	variables	_
76-10	14617-14621	were	_
76-11	14622-14631	corrected	_
76-12	14632-14635	for	_
76-13	14636-14644	multiple	_
76-14	14645-14656	comparisons	_
76-15	14657-14662	based	_
76-16	14663-14665	on	_
76-17	14666-14669	the	_
76-18	14670-14679	inclusion	_
76-19	14680-14682	of	_
76-20	14683-14684	7	_
76-21	14685-14696	independent	_
76-22	14697-14698	(	_
76-23	14699-14702	not	_
76-24	14703-14713	correlated	_
76-25	14714-14715	)	_
76-26	14716-14724	measures	_
76-27	14725-14726	(	_
76-28	14727-14740	Supplementary	_
76-29	14741-14748	Methods	_
76-30	14749-14750	)	_
76-31	14751-14752	.	_

77-1	14753-14763	Additional	_
77-2	14764-14772	analyses	_
77-3	14773-14777	were	_
77-4	14778-14787	conducted	_
77-5	14788-14790	to	_
77-6	14791-14795	rule	_
77-7	14796-14799	out	_
77-8	14800-14809	potential	_
77-9	14810-14820	influences	_
77-10	14821-14823	of	_
77-11	14824-14830	motion	_
77-12	14831-14833	on	_
77-13	14834-14837	the	_
77-14	14838-14845	results	_
77-15	14846-14849	and	_
77-16	14850-14852	to	_
77-17	14853-14860	confirm	_
77-18	14861-14864	ROI	_
77-19	14865-14873	findings	_
77-20	14874-14878	with	_
77-21	14879-14884	whole	_
77-22	14885-14890	brain	_
77-23	14891-14899	analyses	_
77-24	14900-14901	(	_
77-25	14902-14915	Supplementary	_
77-26	14916-14923	Methods	_
77-27	14924-14925	)	_
77-28	14926-14927	.	_

